Pacific Biosciences of California (NASDAQ: PACB) and Bruker (NASDAQ:BRKR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.
Bruker pays an annual dividend of $0.16 per share and has a dividend yield of 0.5%. Pacific Biosciences of California does not pay a dividend. Bruker pays out 13.2% of its earnings in the form of a dividend.
Pacific Biosciences of California has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Bruker has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.
Earnings & Valuation
This table compares Pacific Biosciences of California and Bruker’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pacific Biosciences of California||$93.47 million||4.61||-$92.18 million||($0.87)||-3.76|
|Bruker||$1.77 billion||2.83||$78.60 million||$1.21||26.46|
Bruker has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Bruker, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
71.2% of Pacific Biosciences of California shares are owned by institutional investors. Comparatively, 65.6% of Bruker shares are owned by institutional investors. 13.4% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 36.3% of Bruker shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Pacific Biosciences of California and Bruker’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pacific Biosciences of California||-105.22%||-91.11%||-58.10%|
This is a breakdown of recent ratings and target prices for Pacific Biosciences of California and Bruker, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pacific Biosciences of California||0||2||0||0||2.00|
Pacific Biosciences of California presently has a consensus price target of $5.40, suggesting a potential upside of 65.14%. Bruker has a consensus price target of $32.80, suggesting a potential upside of 2.44%. Given Pacific Biosciences of California’s stronger consensus rating and higher possible upside, equities analysts clearly believe Pacific Biosciences of California is more favorable than Bruker.
Bruker beats Pacific Biosciences of California on 10 of the 16 factors compared between the two stocks.
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, and defect-detection equipment for semiconductor process control, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments and spark optical emission spectroscopy systems. In addition, it offers superconducting and non-superconducting materials and devices. The company serves pharmaceutical, biotechnology and diagnostics, chemical, food and beverage, clinical, polymer, nanotechnology, semiconductor, and industrial companies; nonprofit laboratories; contract research organizations, academic institutions, medical schools, nonprofit or for-profit forensics, agriculture, food and beverage safety, environmental and clinical microbiology laboratories, hospitals, and government departments and agencies; and raw material manufacturers, and other businesses involved in materials analysis. It markets its products through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was founded in 1991 and is headquartered in Billerica, Massachusetts.
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.